www.gbt.com Open in urlscan Pro
35.185.31.195  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content
 * Global+
   * Global
   * France
   * Germany
   * UK
 * Contact Us
 * twitter
 * LinkedIn

gbt
 * Global+
   * Global
   * France
   * Germany
   * UK
 * About+
   * Our Company
   * Contact Us
 * Our Commitment+
   * Patients & Advocacy
   * GBT’s Supported Conferences
   * COVID-19 Information and Resources
   * Corporate Giving
   * The GBT Foundation
   * Expanded Access
   * Environmental, Social and Governance
 * Research+
   * Sickle Cell Disease
   * Pipeline
   * Externally Sponsored Research (ESR)
   * Partnerships
   * Publications
 * Our Medicine
 * Investors
 * Media
 * Careers+
   * Jobs
 * Contact Us
 * twitter
 * LinkedIn

GBT is now part of Pfizer! Click here for more information.

Hope is what feeds us,

connects us and moves us forward. It’s what we bring to life through access to
innovative treatment and determined advocacy.

Learn more



Science is our bedrock, our backbone.

It’s how we make good happen and find ways to answer significant unmet needs.
It’s our promise.

Learn more

Community is our strength and our inspiration.

Patients, their families and healthcare professionals are why we come to work
each day and our reason for being.

Learn more
 * 
 * 
 * 


ADVANCING CARE IN SICKLE CELL DISEASE

We are changing the way treatments for sickle cell disease are developed,
approved and delivered

See our pipeline


PARTNERING WITH THE COMMUNITY

Our deep commitment to the sickle cell community includes helping to create
solutions to help improve the quality of care and access to treatment for
patients

More on our commitment


JOIN OUR PURPOSE-DRIVEN CULTURE

Every GBT colleague has an opportunity to make a difference for underserved
patients

Build your career


LATEST NEWS:PFIZER TO ACQUIRE GLOBAL BLOOD THERAPEUTICS FOR $5.4 BILLION TO
ENHANCE PRESENCE IN RARE HEMATOLOGY

September 15, 2022
Press Release

GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022

September 8, 2022
Press Release

GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle
Cell Disease Therapeutics Conference

August 8, 2022
Press Release

Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence
in Rare Hematology

August 4, 2022
Press Release

GBT Announces New Employment Inducement Grants

August 3, 2022
Press Release

GBT Announces Participation at the Wedbush PacGrow Healthcare Conference

View latest news
gbt

Copyright 2021
Global Blood Therapeutics, Inc.

 * Privacy Policy
 * Online Tracking Opt-Out Guide
 * Terms of use
 * Community guidelines

P-VOX-US-00501

 * About
   * Our Company
   * Contact Us
   * Careers
 * Our Commitment
   * Patients & Advocacy
   * GBT’s Supported Conferences
   * COVID-19 Information and Resources
   * Corporate Giving
   * The GBT Foundation
   * Expanded Access
   * Environmental, Social and Governance
 * Research
   * Sickle Cell Disease
   * Pipeline
   * Externally Sponsored Research (ESR)
   * Partnerships
   * Publications
 * Our Medicine
 * Investors
   * Media
 * Contact Us
 * twitter
 * LinkedIn

This site uses cookies to give you the best online experience. Learn more,
including how to disable certain cookies on our Privacy Page. Accept
Privacy & Cookies Policy
Close

PRIVACY OVERVIEW

This website uses cookies to improve your experience while you navigate through
the website. Out of these cookies, the cookies that are categorized as necessary
are stored on your browser as they are essential for the working of basic
functionalities...
Necessary
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly.
This category only includes cookies that ensures basic functionalities and
security features of the website. These cookies do not store any personal
information.
Non-necessary
Non-necessary
Any cookies that may not be particularly necessary for the website to function
and is used specifically to collect user personal data via analytics, ads, other
embedded contents are termed as non-necessary cookies. It is mandatory to
procure user consent prior to running these cookies on your website.
SAVE & ACCEPT



×


YOU ARE NOW LEAVING THE GLOBAL BLOOD THERAPEUTICS WEBSITE

You are currently leaving our site. External links are being provided as a
convenience and for informational purposes only; they do not constitute an
endorsement or an approval by Global Blood Therapeutics. Are you sure you want
to proceed?
Okay Cancel